drugset / Trial / NCT07293065
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Zoster Vaccine (CHO Cell) | Vaccine | 50 ug | Intramuscular |
| Subject | Recombinant Zoster Vaccine (CHO Cell) | Vaccine | 0.5 ml | Intramuscular |